AKR1C2 and myeloid sarcoma: Thus, it appears that in the case of a balance between AKR1C2 in the reducing direction and HSD17B2 together with HSD17B6 in the oxidative direction, there is no counter-regulation with increasing severity of MS, but on the contrary a further deterioration of the situation from the patient’s perspective.